Global research trends in immunotherapy for head and neck neoplasms: A scientometric study.

Head and neck neoplasms Head and neck squamous cell carcinoma Immunotherapy Nivolumab PD-1 Scientometric

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 22 12 2022
revised: 01 04 2023
accepted: 03 04 2023
medline: 28 4 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

In recent decades, the traditional treatment of head and neck neoplasms has reached a bottleneck with limited improvement in overall survival. Nevertheless, the emerging field of immunotherapy has shown promise. Literature on research into immunotherapy for head and neck neoplasms was retrieved from WoSCC. Citespace was used as a scientometric analysis tool for text mining and visualization of the scientific literature. This analysis included 1915 documents. Recently, the annual number of publications and citations has been growing rapidly. 'Oncology' was the most popular research area. The most dominant institution and country were the University of Pittsburgh and the USA. Ferris RL was not only the most prolific but also the most cited author, demonstrating a strong influence and reputation. Of the ten core journals identified in this field,

Identifiants

DOI: 10.1016/j.heliyon.2023.e15309 PMID: 37113789 PMC: PMC10126860
pubmed: 37113789
doi: 10.1016/j.heliyon.2023.e15309
pii: S2405-8440(23)02516-1
pmc: PMC10126860
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e15309

Informations de copyright

© 2023 The Authors.

Références

Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancers (Basel). 2021 Feb 04;13(4):
pubmed: 33557271
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Clin Cancer Res. 2020 Apr 1;26(7):1616-1623
pubmed: 31727676
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
J Immunother Cancer. 2019 Sep 18;7(1):252
pubmed: 31533840
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
Crit Rev Oncol Hematol. 2020 Jun;150:102966
pubmed: 32371338
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Oncotarget. 2016 Dec 6;7(49):81341-81356
pubmed: 27835902
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Onco Targets Ther. 2018 Jun 28;11:3731-3746
pubmed: 29988729
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Head Neck. 2018 Nov;40(11):2432-2440
pubmed: 30295975
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Radiother Oncol. 2009 Feb;90(2):163-5
pubmed: 19171403
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Int J Mol Sci. 2019 Oct 30;20(21):
pubmed: 31671550
Laryngoscope. 2012 Jan;122(1):144-57
pubmed: 22183634
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
PLoS One. 2013;8(2):e47234
pubmed: 23408925
Mol Cancer Res. 2019 Jan;17(1):120-130
pubmed: 30224542
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Clin Otolaryngol. 2018 Feb;43(1):13-21
pubmed: 28464441
Cancer Biother Radiopharm. 2011 Feb;26(1):1-64
pubmed: 21355777
Clin Otolaryngol. 2012 Oct;37(5):376-81
pubmed: 22943608
PLoS One. 2019 Oct 31;14(10):e0223994
pubmed: 31671124
Cancer Immunol Immunother. 2012 Jun;61(6):771-82
pubmed: 22057678
J Clin Oncol. 2010 Oct 1;28(28):4390-9
pubmed: 20697078
Head Neck. 2011 Dec;33(12):1666-74
pubmed: 21284052
Br J Oral Maxillofac Surg. 2019 Dec;57(10):957-966
pubmed: 31653434
Saudi Med J. 2021 Mar;42(3):247-254
pubmed: 33632902
J Clin Oncol. 2021 Mar 1;39(7):704-712
pubmed: 33492986
Proc Natl Acad Sci U S A. 2004 Apr 6;101 Suppl 1:5303-10
pubmed: 14724295
Oncol Res Treat. 2017;40(6):342-346
pubmed: 28521322
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Oral Oncol. 2020 Dec;111:104928
pubmed: 32738599
Oral Oncol. 2019 Feb;89:95-101
pubmed: 30732966
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Oncoimmunology. 2016 Oct 7;5(11):e1239005
pubmed: 27999760
Anticancer Drugs. 2011 Aug;22(7):674-81
pubmed: 21037467
Oral Oncol. 2015 Apr;51(4):299-304
pubmed: 25624094
Oncoimmunology. 2015 Apr 2;4(5):e1026531
pubmed: 26155408
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967162
Crit Rev Oncol Hematol. 2019 Dec;144:102829
pubmed: 31739116
Cancer Genomics Proteomics. 2013 Sep-Oct;10(5):197-207
pubmed: 24136972
Head Neck. 2018 Sep;40(9):1999-2006
pubmed: 29756246
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544

Auteurs

Zhou Jiang (Z)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Chenzhou Wu (C)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Yiming Zhao (Y)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Qi Zhan (Q)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Kunyu Wang (K)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Yi Li (Y)

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, PR China.

Classifications MeSH